Equities research analysts expect that Viveve Medical Inc (NASDAQ:VIVE) will announce earnings of ($0.36) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Viveve Medical’s earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.41). Viveve Medical posted earnings per share of ($0.53) during the same quarter last year, which suggests a positive year-over-year growth rate of 32.1%. The business is expected to announce its next quarterly earnings results on Thursday, March 21st.
According to Zacks, analysts expect that Viveve Medical will report full-year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.63) to ($1.39). For the next year, analysts forecast that the company will report earnings of ($1.06) per share, with EPS estimates ranging from ($1.32) to ($0.84). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.06). The business had revenue of $4.82 million for the quarter, compared to the consensus estimate of $4.60 million. Viveve Medical had a negative net margin of 239.33% and a negative return on equity of 551.85%.
Separately, ValuEngine lowered shares of Viveve Medical from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.75.
Viveve Medical stock opened at $2.32 on Wednesday. The stock has a market capitalization of $103.60 million, a PE ratio of -1.10 and a beta of -0.25. The company has a debt-to-equity ratio of 3.42, a current ratio of 4.41 and a quick ratio of 4.00. Viveve Medical has a 12-month low of $1.60 and a 12-month high of $5.40.
Several institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA lifted its holdings in shares of Viveve Medical by 117.8% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 792,607 shares of the company’s stock worth $2,156,000 after acquiring an additional 428,708 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Viveve Medical by 11.0% in the 2nd quarter. Marshall Wace LLP now owns 441,279 shares of the company’s stock worth $1,200,000 after acquiring an additional 43,842 shares during the last quarter. Paloma Partners Management Co bought a new stake in shares of Viveve Medical in the 2nd quarter worth about $268,000. RTW Investments LP lifted its holdings in shares of Viveve Medical by 11.9% in the 2nd quarter. RTW Investments LP now owns 2,861,023 shares of the company’s stock worth $7,782,000 after acquiring an additional 303,464 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its holdings in shares of Viveve Medical by 38.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 3,948,132 shares of the company’s stock worth $10,739,000 after acquiring an additional 1,100,928 shares during the last quarter. Hedge funds and other institutional investors own 61.98% of the company’s stock.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Further Reading: How Do Tariffs Affect Trade Balances?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.